NGM Biopharmaceuticals, Inc.
NGM · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $1 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $1 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -92% | -29% | -10.9% | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 49.7% | 89.2% | 89.9% | -87.7% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3,267.5% | -280% | -155% | -118.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3,223.3% | -287.5% | -146.2% | -107.6% |
| EPS Diluted | -1.73 | -1.99 | -1.48 | -1.37 |
| % Growth | 13.1% | -34.5% | -8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |